



Korsuva™ (difelikefalin) – New drug approval

- On August 23, 2021, Vifor Pharma and Cara Therapeutics [announced](#) the FDA approval of [Korsuva \(difelikefalin\)](#), for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).
 - Korsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.
- Korsuva is a novel kappa opioid receptor agonist and the first approved treatment for CKD-aP.
- The efficacy of Korsuva was established in two randomized, double-blind, placebo-controlled studies that enrolled a total of 851 patients 18 years of age and older undergoing HD who had moderate-to-severe pruritus. In both studies, patients received Korsuva or placebo three times per week for 12 weeks. In each study, the primary endpoint was the proportion of patients achieving a 4-point or greater improvement (reduction) from baseline in the weekly mean of the daily 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS) score at week 12 (0 “no itch” to 10 “worst itch imaginable”).
 - In study 1, 40% of patients met the primary endpoint vs. 21% with placebo (difference of 19, 95% CI: 9, 28).
 - In study 2, 37% of patients met the primary endpoint vs. 26% with placebo (difference of 12, 95% CI: 3, 20).
- Warnings and precautions for Korsuva include dizziness, somnolence, mental status changes, and gait disturbances, and risk of driving and operating machinery.
- The most common adverse reactions (incidence $\geq 2\%$ and $\geq 1\%$ higher than placebo) with Korsuva use were diarrhea, dizziness, nausea, gait disturbances, including falls, hyperkalemia, headache, somnolence, and mental status change.
- The recommended dosage of Korsuva is 0.5 mcg/kg administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each HD treatment.
 - Refer to the Korsuva drug label for complete dosing and administration recommendations.
- Vifor Pharma and Cara Therapeutics are planning a promotional launch for Korsuva in the first quarter of 2022. Korsuva will be available as a 65 mcg /1.3 mL injection in a single-dose vial.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.